Fully committed to Africa, Sanofi is the n°1 pharmaceutical company on the continent
Christopher A. Viehbacher, CEO, began a trip which will take him to the Ivory Coast, South Africa and Chad and will reinforce Sanofi's commitment in Africa. This visit is an opportunity to strengthen partnerships with governmental and health authorities, to engage with stakeholders, to meet and discuss with employees and to engage in a dialogue with the media.
Christopher A. Viehbacher and his team will also see first-hand the work Sanofi is supporting in Chad to fight against neglected tropical diseases, such as sleeping sickness. A partnership between Sanofi and the World Health Organisation, established in 2001, has screened over 2 million people for this disease, which is fatal if untreated. Between 2001–2010, over 170,000 patients were treated - 170,000 lives saved. In 2011, Sanofi announced its ongoing commitment to this disease and together, the partnership is on track to eliminate this neglected tropical disease by 2020.
Sanofi, a leading healthcare partner fully committed to Africa
Sanofi is the N°1 pharmaceutical company in Africa with €1 Billion sales in 2011. The Group has been present in this continent for more than 40 years with a double digit growth in the last 10 years. Today, we employ 4 400 people and nearly 60% of our drugs are manufactured locally in 7 production sites in Algeria, Tunisia, Morocco, Egypt, Senegal and South Africa. €80 Million were invested during the last 5 years while investments in the coming 5 years are estimated at €120 Million. We continue to support in some strategic projects such as new product lines (tuberculosis in South Africa, anti-infective in Tunisia, injectable drugs in Egypt, and anti-malaria drugs in Morocco).
We are deeply committed to offering patients in Africa one of the largest portfolios with healthcare solutions in major therapeutic areas: diabetes, cardiovascular, thrombosis, internal medicine, oncology and central nervous system. Through our generic platform, we are constantly extending this portfolio to ensure affordable drugs to more patients in more countries. Moreover, thanks to our vaccines division, Sanofi Pasteur, we provide a broad range of adapted vaccines.
Our Corporate Social Responsibility in Africa
Sanofi is a real partner, working hand in hand with health authorities and healthcare professionals to ensure that the right solutions reach those most in need. Sanofi's Access to Medicine is present in Africa through numerous initiatives in different disease areas: malaria, tuberculosis, epilepsy, and neglected tropical diseases (sleeping sickness, leishmaniasis, Chagas disease and Buruli ulcer). This commitment is ceaselessly reinforced by numerous partnerships.
Sanofi Espoir Foundation is involved in Africa to support national and local healthcare by reinforcing capacity building and access to care. 55% of the Sanofi Espoir projects are developed in Africa.